Collectively, because asporin could bind additional and currently unidentified proteins to regulate different signaling pathways in cancer, it is an interesting direction to globally screen additional asporin-interactive partners through quantitative (measuring dissociation constants) and proteomics (identifying interacting proteins) analyses. The gene discussed is ASPN; the disease is cancer.